VIDEO: B7-H3 "promising new agent" for early line and metastatic prostate cancer

ByCory Perla

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses two posters on prostate cancer therapies presented at the ESMO Congress 2021.

The first is a study on pembrolizumab plus docetaxel and prednisone for patients with abiraterone acetate- or enzalutamide-pretreated metastatic castration-resistant prostate cancer, and the second is a phase II trial of anti-B7-H3 antibody, enoblituzumab in men with localized prostate cancer.

"B7-H3 is a promising new agent in the field of immunotherapy but has a target potential in prostate cancer both in the early line setting and in the metastatic disease," Shenderov said.

Published by:

Sources/Disclosures

Collapse

Source:

Shenderov reports receiving clinical trial institutional research funding from MacroGenics; is the founder and CEO of LifeImmune, Inc; and has served as a consultant for Firstthought and Guidepoint Global.

Disclosures: Shenderov E, et al. Abstract 620p. Presented at: ESMO 2021; Sept. 16-21, 2021 (virtual meeting). Shenderov E, et all. Abstract 627p. Presented at: ESMO 2021; Sept. 16-21, 2021 (virtual meeting).

Take Homes in Prostate Cancer

Read more

VIDEO: B7-H3 "promising new agent" for early line and metastatic prostate cancer

Related Content